NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Take Solutions Enters Longevity and Anti-Aging Segment, Stock Rises

Shares of Take Solutions were locked in the 2% upper circuit on Friday, April 17, following the company's announcement of its entry into India's longevity and anti-aging segment. This strategic move aims to leverage the company's established capabilities in clinical research, life sciences, and regulatory processes to build a scalable platform spanning consumer health products and digital wellness solutions.

The global longevity market, valued at $27.61 billion in 2025, is projected to reach $67.03 billion by 2035, reflecting a compound annual growth rate (CAGR) of 9.41%. In India, the potential for the longevity and anti-aging market is growing, driven by increased health awareness and a rise in lifestyle-related health issues. Take Solutions plans to implement a dual approach that combines product innovation with technology-driven solutions, featuring science-based nutraceuticals, biohacking products, and predictive digital tools aimed at metabolic health, sleep, cognition, and biological aging.

The company's entry into the longevity and anti-aging segment positions it in a rapidly growing and underpenetrated market. Parmeshvar Dhangare, Director of Take Solutions Ltd, stated that the initiative aims to build a diversified revenue mix across consumer products, services, and digital platforms, while leveraging the company's core strengths in healthcare and regulatory execution to deliver scalable and clinically credible solutions.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Take Solutions' share price has shown strong momentum, with the stock gaining 7.54% over the past week and surging 18.66% in two weeks. Over a one-month period, it is up 23.23%, while in the last three months it has advanced 17.43%. On a year-to-date basis, the stock has risen 21.33%, and over the past six months it has delivered an impressive 138.35% return. Most notably, it has delivered a remarkable 468.72% return over the last one year, highlighting a strong uptrend and significant wealth creation for investors.

Technical Analysis

TimeframeGain
Last 1 week7.54%
Last 2 weeks18.66%
Last 1 month23.23%
Last 3 months17.43%
YTD21.33%
Last 6 months138.35%
Last 1 year468.72%

According to Osho Krishan, Sr. Analyst, Technical & Derivatives, Angel One, given the recent circuit-level movements in Take Solutions' stock, relying solely on technical indicators may not provide a comprehensive view. However, based on historical price trends, the stock appears to face a resistance zone around the 50 level. A decisive breakout above this range could potentially drive the price towards the 65–68 zone, while the 44–40 range is expected to serve as a key support zone.

Investor Takeaway

Investors should consider the growth potential of Take Solutions in the longevity and anti-aging segment.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.